Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

422 - PD-L1 blockade during ex vivo expansion of virus-specific T cells for the treatment of infections after allogeneic hematopoietic stem cell transplantation modulates the phenotype and functional activity of T cells

Date

14 Dec 2018

Session

Poster Display session

Presenters

Maysaloun Merhi

Citation

Annals of Oncology (2018) 29 (suppl_10): x11-x16. 10.1093/annonc/mdy485

Authors

M. Merhi1, M. Jalis1, S. Sivaraman2, V. Inchakalody1, A. Raza1, M. Bakr1, G. Pittari1, S. Uddin2, A. Knuth1, S. Dermime1

Author affiliations

  • 1 Medical Oncology, National Center for Cancer Care and Research, 20479 - Doha/QA
  • 2 Translational Research Institute, Hamad Medical Corporation, 3050 - Doha/QA
More

Resources

Abstract 422

Background

Viral infection is a major cause of disease and mortality after allogeneic hematopoietic stem cell transplantation (AHSCT) in hematologic malignancies. It has been shown that adoptive transfer of expanded virus-specific T cells (VSTs) was capable of treating infections that are resistant to conventional therapies. Recently, it has been shown that PD-L1 expression by activated T cells plays a major role on their survival and activity. Here, we investigated PD-L1 expression during VSTs expansion and the effect of PD-L1 blockade on the phenotype and functional activity of these VSTs.

Methods

VSTs were generated from healthy donors PBMCs with or without the addition of PD-L1 antibody after stimulation in G-Rex-10 flasks with a pool of 11 overlapping peptides libraries spanning the 5 most immunodominant viral antigens. All VSTs were collected at day 14. We used ELISpot assay to measure IFN-γ production by VSTs and flow cytometry analysis for phenotyping.

Results

Blockade of PD-L1 has induced 1.8 folds higher proliferation rate and 2 folds increase in IFN-γ production against the viral antigens. After 6 days of expansion, 78% of CD4+ and 60% of CD8+ VST subsets expressed the PD-L1 molecule. At the end of expansion, CD4+ PD-L1+ VSTs were reduced to 6.8% whereas the CD8+ PD-L1+ VSTs were increased to 87.6%. Interestingly, PD-L1 blockade resulted in a further reduction in the CD4+ PD-L1+ population (2.2%), without affecting the CD8+ PD-L1+ VSTs (89.5%). After PD-L1 treatment, the cytotoxicity marker CD107 was slightly increased (1.2 folds) in the CD4+ cells but decreased by 2 folds in the CD8+ VSTs and CD4+ CD45RO+ memory T cells were decreased from 46.1% to 33%.

Conclusions

We have standardized an ex vivo protocol for rapid expansion of VSTs against major viruses causing infection after AHSCT. These VSTs were shown to highly express PD-L1. Blocking of PD-L1 improved the expansion, the anti-viral specificity and the cytotoxicity of these VSTs. This should promote a long-lasting antiviral activity of VSTs in patients undergoing AHSCT. Further investigations are being carried out to confirm these results.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Medical Research Center, Hamad Medical Corporation, Doha, Qatar.

Funding

Medical Research Center, Hamad Medical Corporation, Doha, Qatar.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.